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Urate transport via human PAH transporter hOAT1 and its so from the intestine. The fact that decreased urate clear-
gene structure. ances lead to hyperuricemia in most hyperuricemic pa-
Background. We recently cloned the human organic anion tients indicates an important role of renal urate processing.transporter 1 (hOAT1) as a p-aminohippurate (PAH) trans-
Urate is secreted by the p-aminohippurate (PAH) trans-porter. Whether urate is transported by the PAH transporter in
porter in the rabbit [1] and pig [2], as determined by in-humans remains unclear. Familial juvenile gouty nephropathy
(FJGN) is thought to develop as a result of an abnormality in hibition studies using PAH. Since urate excretion in rats
the urate transporter. and humans is unaffected by PAH, it is still unclear whe-
Methods. To determine if hOAT1 transported urate, the ther urate uses the PAH transporter in these species [3].cellular uptakes of PAH and urate were determined, as were
We cloned the cDNAs of PAH transporters from ratthe inhibition profiles of inorganic anions, and uricosuric and
and human kidneys and designated them OAT1 [4] andantiuricosuric agents using a mouse S2 cell line expressing
hOAT1. The hOAT1 gene was cloned from a genomic library hOAT1 [5], respectively. The latter is the major PAH
using full-length hOAT1-1 cDNA as a probe. The coding re- transporter localized on the basolateral membrane of the
gions of the hOAT1 genes of two sisters with FJGN were
human proximal tubular cell. Urate is transported viasequenced. Also, immunohistochemical fluorescence analysis
OAT1 expressed in Xenopus oocytes [4]. We also dem-of hOAT1 in the kidney of the younger sister with FJGN was
performed. onstrated the possibility that urate was transported via
Results. The Km and Vmax values of urate transport via hOAT1 hOAT1 by showing that PAH transport was inhibited
were 943  84 mol/L and 1286  162 pmol/mg protein/min, by urate [5], though another study showed that PAH
respectively. The order of the IC50 of urate transport via hOAT1 transport via hOAT1 was not inhibited by urate [6].was benzbromarone  probenecid  salicylate or pyrazine
These conflicting results may have been due to the diffi-carboxylic acid. The 10.9 kb hOAT1 gene was found to be
interrupted by nine introns. Mutations in the coding region of culty in detecting urate transport via hOAT1 expressed
the hOAT1 gene from the two sisters with FJGN were undetect- in Xenopus oocytes because these cells themselves prob-
able. Immunohistochemical fluorescent staining showed that ably have a native urate transport system.
hOAT1 in the kidney of the younger sister was similar to that
Our current study establishes a cell line that stablyof control individuals.
expressed high levels of hOAT1, and explores the char-Conclusions. Our data show that hOAT1 transports urate,
and the inhibition profiles of uricosuric and antiuricosuric acteristics of urate transport via hOAT1 and the inhibi-
agents are defined. hOAT1 is not responsible for FJGN in the tion profile of uricosuric and antiuricosuric agents. Fur-
two sisters examined in this study. thermore, we analyzed hOAT1 in two sisters with
familial juvenile gouty nephropathy (FJGN), which is an
autosomal dominant congenital disorder characterized
Urate is the end product of purine metabolism in hu- by hyperuricemia due to decreased renal urate clearance
mans, and is primarily excreted from the kidney and less and chronic renal failure [7, 8].
Key words: para-aminohippurate, organic anion transporter, benzbro- METHODS
marone, probenecid, salicylate, pyrazine carboxylic acid, familial juve-
Materialsnile gouty nephropathy, urate.
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that some of their relatives also had gout and chronic nase (G3PDH). The PCR template from these cells and
the PCR procedure were validated by G3PDH mRNArenal failure. The profile of the sisters can be summarized
as follows. The propositus was 26 years old when she amplification. The primer pairs were as follows: hOAT1,
5-CAGTGGGGACTGCCCTTTCT-3 and 5-GGACwas diagnosed as having gout and chronic renal failure.
Her serum uric acid level was 11.0 mg/dL, and her urinary AATGGACTGGTCCTGG-3; mOAT1, 5-ACCGAG
GGGCCATACAATCA-3 and 5-CACTCCCCCTCCuric acid excretion was 216 mg/day. Her clearance of crea-
tinine and uric acid were 25.0 mL/min and 1.4 mL/min, TCATAGAT-3. The G3PDH primer pair was attached
in the Advantage RT-for-PCR Kit.respectively. Her 24-year-old sister also had gout and
mild renal insufficiency; her serum uric acid concentra-
Immunofluorescence of S2-hOAT1 cellstion was 9.1 mg/dL and she had a urinary uric acid excre-
tion of 188 mg/day. Her clearance of creatinine and uric S2-hOAT1 cells and S2-pcDNA3.1 cells were inocu-
lated onto Lab-Tek II chamber slides (Nalge Nunc Inter-acid were 60.0 mL/min and 1.4 mL/min, respectively.
Their fractional excretions of uric acid were 0.056 and national, Naperville, IL, USA) at a density of 5.0  104
cells per well. After a six-day culture, cells were washed0.023, respectively. These findings indicate that the eleva-
tions in their serum uric acid levels mainly resulted from with Ca2 free phosphate-buffered saline (PBS) and
were fixed in cold acetone. After three washes with Tris-an under-excretion of urinary uric acid, not from its over-
production. These uric acid under-excretions were not buffered saline (TBS; 20 mmol/L Tris, 137 mmol/L NaCl,
pH 7.6), non-specific binding was blocked with 1% bo-simply attributable to renal insufficiency because the re-
nal insufficiency of the younger sister was mild and the vine serum albumin (BSA) in TBS containing 0.3%
Tween 20 (TBS-T) for five minutes. The first antibodyother relatives who had suffered from FJGN already had
hyperuricemia before their renal function decreased. reaction was performed for one hour at room tempera-
ture using a 1:50 dilution of anti-hOAT1 IgG; controlA kidney biopsy taken from the younger sister revealed
renal histological changes compatible with a diagnosis slides received buffer alone. After three washes with
TBS, the slides were incubated with Cy3-conjugated anti-of chronic interstitial nephritis. On the other hand, no uric
acid crystals were observed in the renal tissues. Immuno- rabbit IgG (Jackson Immuno Lab, West Grove, PA,
USA) in 1% BSA/TBS-T for one hour at room tempera-histochemical staining was negative for immunoglobulins
and complement in the glomerulus. This patient went on ture. The slides were then washed again, as outlined
earlier, and stained with SYTO 24 green fluorescent nu-to develop chronic renal failure two years later.
cleic acid stain (Molecular Probes, Eugene, OR, USA).
Establishment of cell line stably expressing hOAT1 The immunofluorescent staining of hOAT1 and nucleic
acid was viewed using FV500 laser confocal microscopyFull length hOAT1-1 cDNA [5] was subcloned into
the Kpn I and Xba I sites of pcDNA3.1() (Invitrogen, (Olympus, Tokyo, Japan) at 1200 magnification. The
XY image was obtained using the manufacturer’s recom-San Diego, CA, USA). Using TfX-50 reagent (Promega,
Madison, WI, USA), hOAT1-1 cDNA–pcDNA3.1() mended settings for the microscope. The XZ image was
created by repetitively scanning the beams across a singleplasmid was transfected into an immortalized cell line
derived from the S2 segment of the renal proximal tubule line while moving the stage of the microscope between
sequential lateral scans. Each image was merged usingof the temperature sensitive SV40 T antigen gene trans-
genic mouse as described [10]. The mouse S2 cell line the software provided by Olympus.
that stably expressed hOAT1-1 (designated S2-hOAT1)
Uptake of PAH and urate by S2-hOAT1 andwas established using 400 g/mL of geneticin (Gibco/
S2-pcDNA3.1 cellsBRL, Gaithersburg, MD, USA). To determine uptake
by the S2 cell line itself, pcDNA3.1() plasmid lacking The kinetic behavior of urate transport was examined
by performing uptake studies in confluent S2-hOAT1the insert was transfected into the same mouse renal cell
line and selected using geneticin (S2-pcDNA3.1). and S2-pcDNA3.1 cells. Both cell lines were cultured
in 24-well plates directly or on a membrane permeable
Characterization of S2-hOAT1 and S2-pcDNA3.1 cells support system consisting of Transwell Polycarbonate
Membranes (Corning, Corning, NY, USA) for two toTo confirm the transcription of hOAT1 cRNA, poly
(A) RNAs were extracted from S2-hOAT1 cells, S2- three days before the uptake studies were performed.
The culture medium, RITC80-7 (IWAKI Glass, Chiba,pcDNA3.1 cells, and C57BL/6 mouse kidney cells using
Poly ATtract system 1000 (Promega) and reverse tran- Japan), contained 5% fetal bovine serum (FBS; Gibco/
BRL), 100 U/mL penicillin and 100 g/mL streptomycinscribed using an Advantage RT-for-PCR Kit (Clontech,
Palo Alto, CA, USA). Polymerase chain reactions (PCRs) (Gibco/BRL), 0.08 U/mL insulin (Shimizu, Shizuoka,
Japan), 10 g/mL transferrin (Boehringer Mannheim,were performed using Ex premix Taq (Takara Shuzo,
Kyoto, Japan) and primer pairs for hOAT1, mouse OAT1 Mannheim, Germany), 10 ng/mL recombinant human epi-
dermal growth factor (Wakunaga, Hiroshima, Japan),(mOAT1) and glyceraldehyde-3-phosphate-dehydroge-
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and 200 g/mL of geneticin. Immediately before the tor sequencing kit and an ABI 310 Genetic analyzer (PE
Applied Biosystems, Foster City, CA, USA).experiment, the medium was replaced by the uptake
solution, that is, Hanks’ solution (in mmol/L; 127 NaCl, The 5-end of hOAT1 first-strand RNA was determined
using 5-Full RACE Core (Takara Shuzo) according to the5.0 KCl, 0.33 Na2HPO4, 0.44 KH2PO4, 0.8 MgSO4, 1.0
MgCl2, 1.8 CaCl2 and 10 Tris, pH 7.4) containing 1 manufacturer’s recommendations. cDNA was synthesized
from human kidney poly (A) RNA (Clontech), usingmmol/L glutamine, 1 mmol/L sodium l-lactate, and 100
mol/L sodium pyruvate. The uptake study was started the 5-end phosphorylated primer TCTGTGCCATT
GAG. After self-ligation, nested PCR was performedby adding the uptake solution containing 14C-urate or
14C-PAH onto the plate or one side of the membrane. using the primer pairs: hOAT-10 (AGGCAGACAGA
CAGAGGTCC) and hOAT-W1 (AGCCTCCTTGGCTAfter 11 minutes, uptake was stopped by washing three
times with ice-cold incubation medium. The cells were GCTCCTCCTTCTT), as well as hOAT-5 (GCAGGGG
CAGCCTGAGTCCT) and hOAT-W2 (TTCCCTTGCthen solubilized with 1N NaOH for 20 minutes, and neu-
tralized with 4N HCl before the addition of Aquasol-2 AGCTTC-TCCTCACTTTG). The amplified DNA was
directly sequenced using the primer hOAT-W2.(Packard Instruments, Meriden, CT, USA) for scintilla-
tion counting. Substrate uptake was calculated by sub- The primers used to PCR amplify the coding region
of the hOAT1 gene in the sisters with FJGN are showntracting the uptake by S2-pcDNA3.1 cells from the up-
take by S2-hOAT1 cells, after it was calibrated using the in Table 1. Genomic DNA was isolated from peripheral
blood cells using a Qiagen blood and cell culture DNAaverage protein content of three other wells in the same
24-well plate used in the uptake study, with the BCA kit (Qiagen, Hilden, Germany). Exons of the hOAT1
gene were amplified using PCR and directly sequencedprotein assay reagent (Pierce, Rockford, IL, USA).
Transcellular PAH transport by S2-hOAT1 cells was the PCR products as described [11].
measured using the membrane permeable support sys-
Western blottingtem. A total of 10 mol/L of cold PAH, 10 nmol/L
14C-PAH and 20 nmol/L 3H-mannitol were applied to Western blotting analysis for whole kidney was per-
formed for characterization of our hOAT1 antibodyeach side of the membrane. Paracellular transport of
PAH was calculated by examining the paracellular trans- (Ab). A whole human kidney was derived from the pa-
tient with xanthinuria who had died of sepsis, after in-port of 3H-mannitol, which was not transported transcel-
lularly. Transcellular transport of PAH was calculated formed consent was obtained from his family. Crude
extract preparation for Western blotting analysis wasby subtracting paracellular transport from the total PAH
transport across the cell layers. performed as follows: After adding 4 vol/wt of PBS con-
taining protease inhibitors (Complete; BoehringerThe effects of inorganic anions, -ketoglutarate, and
uricosuric and antiuricosuric agents on urate transport Mannheim) to 1 vol/wt of kidney tissue, the mixture
was homogenized in a Potter homogenizer on ice. Thevia hOAT1 also were examined by using incubation me-
dia containing each agent together with 14C-urate. The solution was centrifuged at 100,000  g for 30 minutes
at 4C and Western blotting analysis of the supernatantsodium gluconate uptake solution contained 5 mmol/L
CaCl2, which was added in order to maintain Ca ion was performed. After electrophoresis of 0.4 g of speci-
men protein was performed using polyacrylamide gellevels.
To evaluate the influence of acidification of the incuba- (12.5%) and was transferred to a nylon membrane,
hOAT1 protein was stained with diluted (1:100) rabbittion medium on urate transport, the uptake solution was
adjusted to pH 6.0. anti-hOAT1 Ab [5] and the enhanced chemilumines-
cence (ECL) Western blotting analysis system (Amer-The effects of glutarate, a non-metabolized counter
anion, on urate and PAH transport by hOAT1 also were sham Pharmacia Biotech, Buckinghamshire, UK).
examined using the uptake study protocol after preincu-
Immunohistochemistrybating the S2-hOAT1 cells for two hours with or without
glutarate in the preincubation solution. In this experi- The expression of hOAT1 in the kidney was detected
by indirect immunofluorescence based on the avidin-ment, the uptake solution was used without any meta-
bolic substrate. biotin-complex system [12]. After blocking nonspecific
binding using an avidin/biotin-blocking kit (Vector Lab-
Cloning and analysis of the hOAT1 gene oratories, Burlingame, CA, USA), sections were incu-
bated with diluted (1:100) rabbit anti-hOAT1 Ab [5]We screened a human genomic library constructed
with lambda phage (Clontech), using 32P-labeled full overnight at 4C, rinsed in PBS, and incubated for 60
minutes at 37C with biotinylated sheep anti-rabbit IgGlength hOAT1-1 cDNA. The insert of one clone of the
hOAT1 gene was excised from phage arms using XbaI Ab (American Quolex, La Mirada, CA, USA). After rins-
ing in PBS, the sections were incubated with FITC-and subcloned into the pBluescript KS	 XbaI site. The
hOAT1 gene was sequenced using the BigDye termina- labeled avidin (dilution 1:50; Becton Dickinson, San
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Table 1. Primers used for PCR amplification of coding region of hOAT1 gene
Forward Reverse
Name Sequence Positiona Name Sequence Positiona
Primers for amplification and sequencing
Exon 1–7 HOAT-8 GAAAGCTGAGCTGCCCTGAC 12–31 TAOH-2 AGCTTGGCAGGCAGGTCCAC 1426–1407
Exon 4–10 HOAT-2 TTTGCCTTCTTCATCTACTC 1052–1072 TAOH-9 CCTTTTAATGATGTGGTTCT 2152–2133
Primers for sequencing
Exon 1 HOAT-10 AGGCAGACAGACAGAGGTCC 211–230 TAOH-7 AGTGGCTGGGGGCTGAGGCC 261–241
HOAT-5 GCAGGGGCAGCCTGAGTCCT 491–510 TAOH-11 TCTGTGCCATTGAGAAAGGG 562–543
TAOHI-10 CCCCCATCTTCCCATCTTGG Intron 1
Exon 2 HOATI-7 AAGCCAGGCTCATCTCTGCCT Intron 1 TAOHI-11 TGCCAAGCTCCCACCATGACA Intron 2
Exon 3 HOATI-8 AGGGCCCTGCTACAAGTCTCC Intron 2 TAOHI-12 GGAGTGGGCTGGTAAGAATC Intron 3
Exon 4 HOATI-5 AGGTAGTTGCAGCATCCTGT Intron 3 TAOHI-4 TCCTGTGGCAACCACCTCCA Intron 4
Exon 5 & 6 HOATI-2 ACTGCCTCGTGGTCCTAGAG Intron 4
HOAT-12 GATCAATGGGAAGCGGGAAG 1157–1176 TAOHI-9 GTCTCAGTCTGTCTGTCTTTC Intron 6
Exon 7 & 8 HOATI-9 TAAGCCTTCCTAACAAACTCC Intron 6 TAOHI-13 GGCTGTCATTCTCCCATTAG Intron 8
Exon 9 HOATI-10 GACCAGCATGTGGGCATTCA Intron 8 TAOHI-1 TGGACACCTGCTCTCTGCC Intron 9
Exon 10 HOATI-6 GCTGCATACCCAGAGTACCA Intron 9
a Nucleotide residue numbers are according to [5]
Jose, CA, USA) for 60 minutes at 37C. The sections tected on control slides that were treated without pri-
were again rinsed in PBS, then mounted in p-phenylene- mary antibody.
diamine (Sigma, St. Louis, MO, USA)-PBS-glycerin and Data from the uptake studies using the membrane
observed under a Zeiss Axiophot fluorescence photomi- permeable support system showed that the cellular PAH
croscope. Negative controls were performed by replacing uptake following apical application of PAH was similar
the antibody in the first step by incubation buffer alone or to that seen with basal application (Table 2). Similarly,
by an isotype-matched Ab. Tissues from normal human the paracellular and transcellular transports of PAH
kidneys obtained after nephrectomy to remove a local- from the apical to the basal side of the S2-hOAT1 cell
ized neoplasm were used as normal controls. layers were roughly equivalent to those seen in the oppo-
site direction. Thus, PAH uptake did not appear to be
Statistical analysis affected by changing the site of PAH addition.
Uptake experiments were conducted three times, and
Time and concentration dependence of PAH andeach uptake experiment was performed in triplicate. Val-
urate transport via hOAT1ues were presented as the means  standard errors. A
single measurement represented the average of triplicate Figure 2A shows the time dependence of substrate
samples, and the mean represented the average of three (PAH and urate) uptake by S2-hOAT1 and S2-pcDNA3.1
of these triplicate averages. Statistical analyses were per- cells. In S2-pcDNA3.1 cells, the level of PAH uptake was
formed using the unpaired t test. P  0.05 was the cutoff similar to background while the level of urate uptake
for significance. was slightly above background. The uptake of PAH and
urate by hOAT1 increased in an almost linear fashion for
11 minutes, before plateauing. Figure 2B shows the con-
RESULTS centration dependence of PAH and urate transport by
Characterization of S2-hOAT1 cells hOAT1. The results, analyzed with Eadie-Hofstee plots
(inset in Fig. 2B), indicate that both PAH and urate trans-hOAT1 cDNA was able to be amplified from S2-hOAT1
port are carrier-mediated and dependent on the substratecells by reverse transcription-PCR (RT-PCR), but not
concentration according to Michaelis-Menten kinetics.from S2-pcDNA3.1 cells (Fig. 1A). mOAT1 cDNA,
The Km value of PAH transport was 73.1  7.0 mol/Lwhich is native to the mouse S2 segment nephron, was
and the Vmax was 1736  19 pmol/mg protein/min, whileunable to be amplified from either S2-hOAT1 cells or
the Km value of urate transport was 943  84 mol/LS2-pcDNA3.1 cells by RT-PCR.
and the Vmax was 1286  162 pmol/mg protein/min.Immunofluorescent study revealed expression of
Figure 2C shows PAH inhibition of urate uptake byhOAT1 on both the apical and basolateral surfaces as
S2-hOAT1 and S2-pcDNA3.1 cells. Urate uptake by S2-well as in the cytoplasm of S2-hOAT1 cells cultured on
hOAT1 cells was inhibited by PAH in a dose-dependentglass slides, while there was only minimal Cy3 staining
manner with an inhibitor concentration that yielded aon S2-pcDNA3.1 cells (Fig. 1B). The expression of hOAT1
half-maximal inhibition (IC50) of 127 mol/L. Urate up-in the cytoplasm was comparable to that on the apical
and basolateral membranes. No labeling was ever de- take by S2-pcDNA3.1 cells was not inhibited by PAH.
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Fig. 1. Characteristics of S2-hOAT1 and S2-
pcDNA3.1 cells. (A) RT-PCR amplification
of hOAT1, mouse OAT1, and G3PDH cDNA
from the poly(A) RNA of S2-hOAT1 cells,
and that of S2-pcDNA3.1 cells. RT-PCR am-
plification of mouse OAT1 from poly(A)
RNA of mouse kidney is shown also. (B) Im-
munofluorescence of hOAT1 on S2-hOAT1
cells and S2-pcDNA3.1 cells cultured on slide
glass. The left panel shows the XY image of
S2-pcDNA3.1 cells by laser confocal micros-
copy, and the right upper panel shows the
XY image of S2-hOAT1 cells. The right lower
panel shows the XZ image of S2-hOAT1 cells.
Table 2. PAH uptakes by S2-hOAT1 cells cultured on the membrane permeable support
Apical application of 10 mol/L PAH Basal application of 10 mol/L PAH
pmol/min/well
14C-PAH uptake 0.860.12 0.560.03
Paracellular 14C-PAH transport 1.700.04 1.610.05
Trans-cellular 14C-PAH transport 1.650.22 2.070.08
Effects of inorganic and organic anions on urate choline chloride (Fig. 3A). Urate transport decreased to
transport via hOAT1 48.5  2.6% in media in which sodium gluconate was
substituted for sodium chloride (P  0.01). Urate trans-Although the intracellular pH was slightly acidified
port was cis-inhibited up to 9.2  1.2% by 1.0 mmol/Lby choline chloride substitution (data not shown), urate
probenecid (P  0.01), 64.2  4.1% by 2.0 mmol/Ltransport via hOAT1 did not change significantly in Na-
free media in which sodium chloride was substituted with 4,4-Diisothiocyanatostilbene-2,2-disulfonic acid (DIDS;
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Fig. 2. Time course and concentration dependence of urate and PAH uptake via hOAT1. (A) Closed circles and squares with solid lines represent
the time course of urate uptake by S2-hOAT1 cell () and that by S2-pcDNA3.1 cell (), respectively. Urate uptake proceeded in Hank’s buffer
containing 290 mol/L cold urate and 10 mol/L 14C-urate. Open circles and squares with dotted lines represent the time course of 4 mol/L 14C-
PAH uptake by S2-hOAT1 cells () and that by S2-pcDNA3.1cells (), respectively. Vertical axes on the left and right sides represent cellular
urate and PAH uptake, respectively. (B) Closed circles with solid lines and open circles with dotted lines represent urate () and PAH ()
transport via hOAT1 at various substrate concentrations, respectively. Uptake proceeded at 37C for 11 minutes. Transport was calculated by
subtracting the uptake by S2-pcDNA3.1 cells from that by S2-hOAT1 cells. Lines were predicted using Vmax and Km values derived from an Eadie-
Hofstee plot of urate and PAH transport via hOAT1 (inset). (C ) Various concentrations of PAH were added to the uptake solution containing
290 mol/L cold urate and 10 mol/L 14C-urate. Closed circles and open circles represent the inhibition of urate uptake by S2-hOAT1 () and
that by S2-pcDNA3.1 cells (), respectively. Inhibition is expressed as percentage of control urate uptake of S2-hOAT1 cells. Lines were predicted
based on competitive inhibition. *P  0.05 vs. control uptake, **P  0.01 vs. control uptake.
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Fig. 4. Inhibition of urate transport via hOAT1 by probenecid and
benzbromarone. Various concentrations of probenecid or benzbromar-
one were added to the uptake solution containing 290 mol/L cold
urate and 10mol/L 14C-urate. Inhibition of urate transport is expressed
as a percentage of control uptake measured in the absence of probenecid
and benzbromarone. Symbols are: () inhibition by probenecid; ()
inhibition by benzbromarone. Lines were predicted based on competi-
tive inhibition. **P  0.01 vs. control uptake.
Fig. 3. Modulation of urate transport via hOAT1 by inorganic and
organic anions. (A) Modulation of 290mol/L cold urate and 10mol/L
14C-urate transport by various ions was expressed as a percentage of
control uptake. Sodium chloride (127 mmol/L) in the uptake solution
was replaced by 127 mmol/L choline chloride or 127 mmol/L sodium glu-
conate to provide Na-free or Cl	-free uptake solutions, respectively. Fig. 5. Inhibition of urate transport via hOAT1 by pyrazine carboxylic
For intracellular acidification, urate transport was studied at pH 6.0 af- acid (PZA) and salicylate. Various concentrations of PZA or salicylate
ter preincubation in 30 mmol/L NH4Cl for 2 hours. The effects of organic were added to the uptake solution containing 290 mol/L cold urate
anions on urate transport via hOAT1 were determined using the uptake and 10 mol/L 14C-urate. Inhibition of urate transport is expressed
solutions containing each reagent at the indicated concentrations. **P as a percentage of control uptake measured in the absence of PZA
0.01 vs. control. (B) Modulation of urate and PAH transport by glutarate or salicylate. Symbols are: () inhibition by PZA; () inhibition by
preincubation. Glutarate 200 mol/L was used for the urate uptake salicylate. Each point represents a value derived from one well. **P 
study and 1 mmol/L glutarate was used for the PAH uptake study. Cold 0.01 vs. control uptake; *P  0.05 vs. control uptake.
urate 990mol/L and 14C-urate 10mol/L were used in the urate uptake
study and cold PAH 100 mol/L and 14C-PAH 5 nmol/L were used in
the PAH uptake study, respectively. Symbols are: () urate and PAH
uptake using the preincubation solution without glutarate; () urate
-Ketoglutarate 2 mmol/L attenuated urate transport viaand PAH uptake using the preincubation solution with glutarate.
hOAT1 to 12.4  1.7% (P  0.01), but 10 mmol/L
l-lactate had no effect.
In the uptake studies preincubated with 1 mmol/L
P  0.01), and 42.9  9.7% by 1.0 mmol/L unlabeled glutarate, the PAH uptake was stimulated to 157.9 
urate (P  0.01), respectively. 8.7% (P  0.05; Fig. 3B). The urate uptake was stimu-
Urate transport increased to 140.3  3.5% (P  0.01) lated to 125.4  8.3% by 200 mol/L glutarate preincu-
when the uptake solution was acidified from pH 7.4 to bation (P  0.05).
pH 6.0. In the urate uptake study using the pH 6.0 uptake
Effects of uricosuric and anti-uricosuric agents onsolution followed by the preincubation with 30 mmol/L
urate transport via hOAT1NH4Cl, urate uptake by S2-hOAT1 cells was less than the
uptake by S2-pcDNA3.1 cells. As a result, the subtracted Figures 4 and 5 show transport inhibition curves for
various uricosuric and antiuricosuric agents when using aurate uptake decreased to 	17.9  0.9% (P  0.01).
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Fig. 6. Organization of the hOAT1 gene and the exon positions and membrane-spanning secondary structure of hOAT1-1. (A) Genomic organiza-
tion of the hOAT1 gene. Horizontal line indicates gene introns and boxes indicate exons. (B) Filled portions of exons indicate protein-coding
sequences, and number in each box is the size of each exon in bp. (C ) Predicted secondary structure of hOAT1-1. Each circle represents one
amino acid. A chain of open or closed circles indicates that corresponding amino acids were derived from the same exon. Circles with broken
lines in exon 9 represent 13 amino acids that were defective in hOAT1-2.
urate concentration of 300 mol/L. Probenecid and benz- initiation site was determined as the cytosine 279 bp
upstream of the first ATG by rapid amplification ofbromarone significantly inhibited urate transport in a
cDNA ends method.dose-dependent manner at concentrations ranging from
Figure 6 and Table 3 show that the hOAT1 gene is inter-10mol/L to 1 mmol/L and from 1mol/L to 100mol/L,
rupted by nine introns. We previously cloned hOAT1-1respectively. The IC50 of benzbromarone was 4.6  0.99
and hOAT1-2 from a human kidney cDNA library. Themol/L, which was lower than that of probenecid, which
hOAT1-1 clone contained a 1689 bp open reading framewas 12.5 4.1mol/L. Salicylate and pyrazine carboxylic
while the hOAT1-2 clone lacked 39 bp of hOAT1-1’sacid (PZA) significantly inhibited urate transport at con-
open reading frame [5]. Comparisons of the hOAT1centrations over 100 mol/L (P  0.01) and 300 mol/L
genomic sequence with hOAT1-1 and hOAT1-2 re-(P  0.05), respectively. The IC50 of salicylate was vealed that the two clones resulted from the use of alter-1573.4  454.9 mol/L and that of PZA was 582.6 
native 5-splice sites in exon 9. As shown in Table 3, all of178.8 mol/L.
the intron/exon boundaries followed GT/AG consensus.
Based on the above findings concerning the exon-Cloning and analysis of the hOAT1 gene in
intron junction of hOAT1, we directly sequenced thetwo siblings with FJGN
coding region of the hOAT1 gene from the two sisters
Two hOAT1 genomic clones were obtained by screen- with FJGN, and found no mutations (data not shown).
ing approximately 400,000 plaques of a human genomic
Western blotting and immunohistological analysis oflambda phage library. A 10.9 kb insert containing the
hOAT1 protein of the kidneyentire hOAT1 gene was obtained from a single clone.
The hOAT1 genomic clone included 2.5 kb sequences of A clear band at 66 kD corresponding to hOAT1 was
detected by Western blotting of the whole kidney samplehOAT1 upstream from the first ATG. The transcription
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Table 3. Nucleotide sequence of intron/exon boundaries of hOAT1
Intron number Exon Intron (size) Exon
369
1 GTG ACT GAG gtgagcacctggggc . (274) . . . . . tctctgcctgacccttgctcctctccccacag TGG GAC CTT
V T E W D L
123
473
2 T GCA GAC AG gtcagtcctgggta . (252) . . . . . ggccctgctacaagtctcccctcctcccacag G CTA GGC CGC
A D R L G R
158
628
3 ATG ACA CTG A gtgagagattcttac . (1.5kb) . . . . gtagttgcagcatcctgtcttaaccctctttccag AT GTG GAG T
M T L N V E
209
797
4 C TAC TCC TG gtgcgtggggcctagggt . (453) . . . . . atgctgacacccacccccacccccgctcccag G TTC TTC ATT
Y S W F F I
266
921
5 AGT ATG GAG gtgagatcccctgag . (159) . . . . . tcccgggccctgagctctgccggtcccagcag GTA CTC CGG
S M E V L R
307
1037
6 C ATG CTG TG gtaggcccagaaaga . (1.0 kb) . . . . caaactccatactcctctcttctctctgctag G TTT GCC ACT
M L W F A T
346
1252
7 TA CCC CAG G gtgagcacccacgag . (137) . . . . . gctcctgctatccccccttctttctctctag AC CAG TCC A
I P Q D Q S
417
1361
8 A ATG ATC CG gtgagtgggagccta . (2.0 kb) . . . . taaccaacacccatctgctgcgggccctgcag G CAG ACA GGC
M I R Q T G
454
1565
9(hOAT1-2) G GAG AGC AG gtgggcccccactca . (302) . . . . . acccagagtgccattcttctgccgccctgcag G AAA GGG AAA
E S R K G K
522
1604
9(hOAT1-1) A TAT CCC AG gtaacacatgcaggg . (263) . . . . . acccagagtgccattcttctgccgccctgcag G AAA GGG AAA
Y P R K G K
535
Intron is represented by lower-case letters, and exon by upper-case letters. Numbers shown above the nucleotide sequence are counted from the first ATG codon
in the cDNA, and the deduced amino acids are indicated below the sequences. Intron sizes are indicated in parentheses. Bold letters indicate the sequences that are
identical with GT/AG consensus at the 5- and 3-splice junctions.
(Fig. 7A). While there was also a band at 130 kD, it was DISCUSSION
faint in comparison to the band at 66 kD and, therefore, Urate transport via hOAT1
was thought not to influence the immunohistochemical In the human kidney, urate is bi-directionally trans-
studies. ported, being both secreted and reabsorbed. Since the
Immunohistochemical studies revealed that hOAT1 under-excretion of urate has been implicated in the de-
protein was localized along the basolateral membrane of velopment of hyperuricemia that leads to gout, it was
proximal tubular cells as previously described (Fig. 7B) important to understand the mechanism of urate trans-
[5]. As shown in Figure 7C, hOAT1 protein also was ob- port in the kidney. Physiological studies using renal
served clearly along the basolateral membrane of proxi- membrane vesicles suggested that both a voltage-sensi-
mal tubules in the kidney of the younger sister with FJGN tive pathway and urate exchangers were located at each
as well as in a control individual. In contrast, no specific of the luminal and basolateral membranes of proximal
staining for hOAT1 was detected in kidney sections that tubule cells in the kidney [13]. As a candidate voltage-
sensitive pathway, UAT and human UAT were clonedwere not treated with anti-hOAT1 Ab (Fig. 7D).
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Fig. 7. hOAT1 protein expression in proximal tubules (original magnification 400). (A) Western blotting for hOAT1 protein in the human
kidney protein using rabbit anti-hOAT1 antibody (Ab). Extract from the whole kidney was subjected to SDS polyacrylamide (12.5%) gel
electrophoresis; a lane contained 0.4 g protein. Positions of molecular markers are shown at the left side of the panel. The 66 kD band corresponds
to hOAT1. (B and C ) Frozen, cryostat sections of kidney were stained with rabbit anti-hOAT1 Ab using a FITC-labeled avidin-biotin complex
as described in the Methods section. (B) hOAT1 protein was observed along the basolateral membrane of proximal tubule cells, but not in the
distal tubules in normal kidneys. (C) hOAT1 protein expressed along the basolateral membrane of proximal tubule cells derived from the younger
sister with FJGN. (D) No specific staining for hOAT1 was found in kidney sections stained after treatment without anti-hOAT1 Ab.
from rat and human kidneys [14, 15]. A recent report transporters on the basolateral membrane have not been
identified. Whether or not the PAH transporter func-suggested that human UAT was localized on the brush
border membrane of proximal tubule cells [16], while a tions as the urate exchanger has been a matter of debate.
Our current study examined the characteristics of uratevoltage-sensitive pathway on the basolateral membrane
was not identifiable. With regard to urate exchangers, transport via the hOAT1, PAH transporter.
We used the hOAT1 gene that was transfected andNPT1 was reported to be a candidate urate exchanger
at the brush border membrane [17]. However, urate stably expressed in a mouse S2 segment cell line. It has
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been difficult to establish any cell lines that highly ex- that the calculated amount of urate transport via hOAT1
is appropriate.press hOAT1 except for the S2 segment cell line, sug-
Since there have been no reports detailing the charac-gesting that the S2 cell line might provide the needed
teristics of urate transport using basolateral membranecellular machinery for expressing hOAT1. Since these
vesicles derived from the human kidney, our knowledgecells don’t express mouse OAT1, subtracting the uptake
of the characteristics of urate transport have been de-by S2-pcDNA3.1 cells from the uptake by S2-hOAT1
rived exclusively from rat basolateral membrane vesiclecells should provide the transport mediated by hOAT1.
studies. At the rat basolateral membrane, urate is trans-Figure 1B shows that hOAT1, which was originally
ported mainly by the urate/chloride exchanger [13] andreported to be located on the basolateral membrane of
also somewhat by the urate/hydroxyl ion exchanger [21].proximal tubule cells in the human kidney, was expressed
Rat urate uptake was shown to be stimulated by theon both the apical and basolateral membrane as well
outward Cl	 gradient using 95 mmol/L gluconate as theas in the cytoplasm of S2-hOAT1 cells. However, only
major anion in the extravesicular solution [22]. In ourhOAT1 expressed on the membrane was capable of
uptake study using the hOAT1 expression cell, uratetransporting substrates. The S2 cell line was immortal-
transport via hOAT1 was not attenuated by the substitu-ized with the SV40 large T antigen and as such, has lost
tion of external Cl	 with gluconate anion (Fig. 3A). Wesome of its epithelial cell specific characteristics, a fact
previously reported that PAH transport via hOAT1 inwhich may have accounted for the loss in polarity of
hOAT1-injected oocytes also was attenuated by the sub-hOAT1 expression. Table 2 shows that the hOAT1 mole-
stitution of external Cl	 with gluconate anion but notcule on both membranes was functional, and cellular
with SCN anion [5]. Therefore, this attenuation was notaccumulation and transcellular transport of PAH from
due to the removal of the external Cl	 ion but to thethe apical as well as basal sides of the S2-hOAT1 cells
presence of external gluconate anion. The stimulationwas observed. The loss of hOAT1 expression polarity
of urate uptake by external chloride removal in the ratcoupled with the similarity in cellular accumulation that
renal vesicle study indicated that this urate/chloride ex-was found when applying hOAT1 substrate to each side
changer of the vesicle was not attenuated by the presenceof the membrane, allowed us to perform uptake studies
of external gluconate anion. Accordingly, hOAT1 is notby applying substrates to the apical side of the cells.
a candidate homolog molecule for the urate/chloride ex-Our data showed that urate transport was carried out
changer in rat renal vesicles that is accelerated by theby hOAT1. This transport is likely not saturable in vivo,
substitution of external Cl	 with gluconate anion. Fur-since the value of the affinity constant of urate transport
thermore, the urate transport by the urate/chloride ex-via hOAT1 was about three times higher than the human
changer in the rat vesicle study was cis-inhibited 39 
serum urate level (300 mol/L). Accordingly, hOAT1
6% by 2.4 mmol/L probenecid, 49  10% by 2.4 mmol/L
should respond to a physiological elevation in serum DIDS, and 35  3% by 1.4 mmol/L unlabeled urate, and
urate level by increasing urate transport. not cis-inhibited by 4.8 mmol/L PAH [22]. The inhibition
The maximum velocity of PAH secretion (TmPAH) of urate transport via hOAT1 by 2 mmol/L DIDS and
in the human kidney was reported to be 77.5  12.9 2 mmol/L unlabeled urate in our study was similar to
mg/min [18]. Thus, if hOAT1 is in fact the sole PAH that by the urate/chloride exchanger in the rat vesicle
transporter on the basolateral membrane, then its rate study, but the inhibition by PAH and 1 mmol/L probene-
of urate transport is about 1.7 times greater than the cid was different. That is, PAH inhibited the urate trans-
amount of glomerular-filtered urate. From the viewpoint port via hOAT1 and 1 mmol/L probenecid inhibited the
of renal urate processing, mammals can be classified into urate transport via hOAT1 more strongly than that via
urate reabsorption dominant species such as humans, and the urate/chloride exchanger in the rat vesicle study.
urate secretion dominant species such as the rabbit and These data support the conclusion that hOAT1 is not a
pig. In both cases, urate transport is bi-directional and the urate/chloride exchanger. The mechanism by which the
urinary urate excretion is the sum of secreted and non- outward Cl	 gradient attenuates urate and PAH trans-
reabsorbed urate after glomerular filtration. The frac- port by hOAT1 remains to be investigated.
tional excretion of human urate (FEurate) is approximately Slight intracellular acidification by sodium removal
10%, but this value can increase up to about 150% in did not significantly change urate transport via hOAT1.
patients with renal hypouricemia, a finding suggested to However, acidification of the incubation media to pH 6.0
be the result of a urate reabsorption defect [19, 20]. augmented urate transport via hOAT1, while intracellu-
Furthermore, the FEurate of the pig is 210% at physiologi- lar acidification induced by preincubation with NH4Cl
cal plasma urate concentrations [2] and that of the rabbit attenuated transport. Thus, urate transport via hOAT1
reached 270%, as the plasma urate concentration was was not dependent on extracellular acidity, but on the
increased to the range of 200 to 310 mol/L by an infu- H-gradient across the cell membrane. Accordingly, it is
conceivable that hOAT1 could be a urate/hydroxyl ionsion of lithium urate [1]. These data support the notion
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exchanger or, alternatively, that the intracellular concen- nism for probenecid because of the high IC50 value of
salicylate for urate transport via hOAT1 and low IC50 oftration of counter anion for urate transport may be in-
fluenced by the acidification of the extracellular space. salicylate for urate transport at the brush border mem-
brane of the human kidney [27].Alpha-ketoglutarate, which is maintained by the so-
dium dicarboxylate cotransporter at a higher concentra- Urate secretion is significantly inhibited by PZA.
Some reports have indicated that the antiuricosuria in-tion intracellularly than in the serum [23, 24], inhibited
urate transport via hOAT1 (Fig. 3A). We previously duced by PZA was due to enhanced urate reabsorption
at the brush border membrane [27, 30, 31]. The serumreported that PAH uptake by rat OAT1 was enhanced
by preincubating the rat OAT1 cRNA injected oocyte concentration of PZA never surpassed 0.15 mmol/L when
3 g of pyrazinamide, the precursor of PZA, was orally ad-with glutaric acid [4]. Figure 3B shows that PAH and
urate transports via hOAT1 were enhanced also by glu- ministered [32]. At that concentration, urate transport
via hOAT1 was not inhibited in our study. This resulttaric acid preincubation. By not adding into the preincu-
bation medium any substances that increased tricarbox- is consistent with the fact that PAH clearance is not
affected by pyrazinamide. Consequently, our result indi-ylic acid cycle substrates, which when metabolized in the
cells could have interfered with hOAT1 transport (data cated that the inhibition of urate secretion by PZA was
not caused by inhibition of urate uptake into the proxi-not shown), we were able to prove that glutaric acid en-
hanced urate transport via hOAT1. These results indi- mal tubule cells at the basolateral membrane, but rather
by enhancement of urate reabsorption at the brush bor-cate that alpha-ketoglutarate is a counterpart for urate
transport via hOAT1. der membrane.
The antiuricosuric effect of uricosuric agents used at
Structure and analysis of the hOAT1 gene oflow doses is referred to as the “paradoxical effect” [25, 26].
the siblings with FJGNThe uricosuric agents had low affinity for the apical volt-
age-sensitive pathway through which urate should be We cloned the hOAT1 gene and analyzed its structure.
Recently, the hOAT1 gene was reported by others tosecreted from human kidney [27]. Accordingly, urico-
suric agents were not responsible for the paradoxical have a structure similar to what we have reported with
the exception being that our clone is about 2 kb longer ineffect at the brush border membrane. Urate uptake inhi-
bition at the basolateral membrane remains a potential the 5 direction [33]. The sequence of our hOAT1 gene
suggested that hOAT1-2 uses a cryptic 5-splice site inmechanism for the paradoxical effect. The IC50 values
of probenecid and benzbromarone for the urate ex- exon 9 that lacks 39 bp of hOAT1-1. Some alternatively
spliced forms of mRNAs arising from a cryptic 5-splicechanger at the brush border are 150 and 0.3 mol/L,
respectively [27]. The therapeutic serum concentrations site such as those transcribing the calcium pump [34]
and human acid sphingomyelinase have been reportedof oral probenecid and benzbromarone reach 530 mol/L
and about 2 to 4mol/L, respectively [28, 29]. The IC50 of also [35]. Our previous report demonstrated that both
hOAT1-1 and hOAT1-2 were not artifacts of cDNA li-urate transport via hOAT1 for probenecid in the present
study (12.5 mol/L) was lower than the therapeutic se- brary construction by RT-PCR of human kidney poly
(A) RNA, but could transport organic anions usingrum concentration of probenecid. Thus, urate transport
via hOAT1 would be inhibited at the low dose of proben- Xenopus laevis oocytes injected with hOAT1-1 cRNA
or hOAT1-2 cRNA. Whether or not the alternative splic-ecid and the urate exchanger at the brush border mem-
brane would be inhibited at the therapeutic dose. Benz- ing of hOAT1 has a function in urate transport systems
remains unknown.bromarone would not suppress urate transport at even
the therapeutic serum concentration because the IC50 of Because hOAT1 would likely transport urate from the
blood into the proximal tubule cells as the first step ofurate transport via hOAT1 for benzbromarone (4.6
mol/L) was higher than the therapeutic serum concen- urate secretion, a deficiency in hOAT1 should elevate
serum uric acid levels. Abnormal urate transport hastration of benzbromarone. Consequently, the IC50 values
found in the present study could account for the paradox- been implicated in the development of FJGN, which is
characterized by hyperuricemia and chronic renal fail-ical effect of probenecid and the absence of such an ef-
fect by benzbromarone, though the stimulation of urate ure. We performed immunohistological analysis of hOAT1
protein in the kidney of a younger sibling, and analyzedreabsorption also remains as a candidate mechanism for
the paradoxical effect. On the other hand, salicylate in- the coding region of the hOAT1 gene of both sisters
with FJGN. Mutations in the coding region of the hOAT1hibited urate transport via hOAT1 at concentrations over
1 mmol/L in the present study. Salicylate has an antiuri- gene were not detected and hOAT1 staining of biopsy
samples from the younger sister and a control individualcosuric and uricosuric effect at serum concentrations
ranging from 90 to 625 mol/L and over 625 mol/L, were essentially identical. Therefore, hOAT1 did not ap-
pear to be responsible for the development of FJGN inrespectively. Accordingly, the mechanism of the para-
doxical effect of salicylate must differ from the mecha- these siblings, though the hyperuricemia associated with
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15. Lipkowitz MS, Leal Pinto E, Rappoport JZ, et al: FunctionalFJGN might be attributable to other urate transporters
reconstitution, membrane targeting, genomic structure, and chro-on the basolateral membrane or the brush border mem- mosomal localization of a human urate transporter. J Clin Invest
brane. Furthermore, hyperuricemia in patients with FJGN 107:1103–1115, 2001
16. Hyink DP, Rappoport JZ, Wilson PD, et al: Expression of themight be secondary to interstitial lesions, tubular cell
urate transporter/channel is developmentally regulated in humandamage, or a lack of the driving force for hOAT1 such
kidneys. Am J Physiol 281:F875–F886, 2001
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In conclusion, our data show that hOAT1 can trans- transport at renal apical membrane mediated by human inorganic
phosphate transporter NPT1. Biochem Biophys Res Commun 270:port urate, a finding that should help begin to unravel
254–259, 2000the mechanism of urate transport by the kidney. In addi- 18. Chasis H, Redish J, Golding W, et al: The use of sodium
tion, we show that hOAT1 was not implicated in the p-aminohippurate for the functional evaluation of the human kid-
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cemia due to isolated renal tubular defect. Attenuated response
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